Dr William Parker
MA, MB, BChir, MRCS, MRCP
Department of Infection, Immunity and Cardiovascular Disease
Clinical Research Fellow (Staff Candidate PhD)
+44 114 226 6159
Full contact details
Department of Infection, Immunity and Cardiovascular Disease
The Cardiovascular Research Unit (CVRU), Sam Fox House
Northern General Hospital
Herries Road
Sheffield
S5 7AU
- Profile
-
I studied Medicine and Pharmacology at the University of Cambridge before returning to my home city of Sheffield to complete the Academic Foundation and Core Medical Training Programmes.
I obtained Membership of the Royal College of Surgeons of England in 2013 and of the Royal Colleges of Physicians of the United Kingdom in 2014.
In 2015, I was appointed Clinical Research Fellow in Cardiology at the University of Sheffield with clinical tenure at the South Yorkshire Cardiothoracic Centre, Northern General Hospital.
In 2018, I was awarded a three-year British Heart Foundation Clinical Training Fellowship and am currently studying for a PhD under the primary supervision of Professor Rob Storey.
- Research interests
-
My main research interest is in improving the quality and safety of anti-thrombotic therapy for ischaemic heart disease.
Specifically, I am currently investigating the dose-dependent effects of aspirin when used in combination with other antithrombotic agents and how drug regimens can be optimised to augment benefits whilst reducing harm.
I have a general interest in the pharmacological management of cardiovascular disease and how this can be improved and investigated.
I also study and research the history of medicine and am in the process of completing the Diploma in the History of Medicine at the Society of Apothecaries of London.
Current Projects:
- The WILLOW programme (a series of randomised controlled trials investigating the dose-dependent effects of aspirin in combination with other antithrombotic drugs).
- Co-investigator on a wide range of local and multi-centre clinical trials within the Cardiovascular Research Unit.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Combining DAPT with a PPI faces the acid test of real-world use. European Heart Journal, 40(24), 1971-1974.
- Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets, 30(2), 148-157. View this article in WRRO
- Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets, 30(5), 579-588.
- Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
- Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study). Thrombosis and Haemostasis, 118(07), 1250-1256. View this article in WRRO
- Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis, 117(06), 1093-1100.
- Ticagrelor: agonising over its mechanisms of action. Blood, 128(23), 2595-2597.
- Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus. Circulation, 134(11), 793-796. View this article in WRRO
- Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart, 102(10), 783-789.
- International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature. Pharmacological Reviews, 61(1), 1-8.
- Choosing a perspective on mortality with DAPT. European Heart Journal, ehv610-ehv610.
Chapters
All publications
Journal articles
- Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention : a GLOBAL LEADERS substudy. Platelets. View this article in WRRO
- Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. European Heart Journal Supplements, 22(Supplement_M), M26-M34.
- Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus : a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Cardiovascular Diabetology, 19(1). View this article in WRRO
- Acoustic shock: an update review. The Journal of Laryngology & Otology, 134(10), 848-853.
- 51 Adherence to cardiologist recommendations regarding extended duration of ticagrelor for patients undergoing PCI for myocardial infarction. Heart, 106(Suppl 2), a41-a41.
- Glimpsing Into the miRe of Ischemia Reperfusion Injury. Transplantation, 104(9), 1769-1771.
- Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y12 receptor antagonist. Expert Opinion on Emerging Drugs. View this article in WRRO
- Opiates and Clopidogrel Efficacy. Journal of the American College of Cardiology, 75(3), 301-303.
- Comparison of Contemporary Drug-eluting Coronary Stents – Is Any Stent Better than the Others?. Heart International, 14(1), 34-34.
- Combining DAPT with a PPI faces the acid test of real-world use. European Heart Journal, 40(24), 1971-1974.
- Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets, 30(2), 148-157. View this article in WRRO
- Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets, 30(5), 579-588.
- Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
- Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study). Thrombosis and Haemostasis, 118(07), 1250-1256. View this article in WRRO
- Secondhand Hypertrophy. Transplantation, 102(9), e397-e398.
- Dual antiplatelet therapy in the ‘real world’. Heart, 104(19), 1555-1556.
- Long-term treatment-related morbidity in differentiated thyroid cancer: a systematic review of the literature. Pragmatic and Observational Research, 8, 57-67. View this article in WRRO
- Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis, 117(06), 1093-1100.
- Ticagrelor: agonising over its mechanisms of action. Blood, 128(23), 2595-2597.
- Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus. Circulation, 134(11), 793-796. View this article in WRRO
- Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart, 102(10), 783-789.
- ‘Acoustic shock’: A new occupational disease? Observations from clinical and medico-legal practice. International Journal of Audiology, 53(10), 764-769.
- Cystic swellings of the neck. Surgery (Oxford), 27(12), 530-534.
- International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature. Pharmacological Reviews, 61(1), 1-8.
- Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy?. European Journal of Preventive Cardiology.
- Antithrombotic therapy for patients with chronic coronary syndromes. Heart.
- Aspirin after PCI: in the twilight of its years?. Platelets, 1-3.
- Benefits and Challenges of Robotic Pelvic Surgery in a Cardiac Transplant Recipient. Surgical Innovation, 155335062093600-155335062093600.
- Novel approaches to P2Y12 inhibition and aspirin dosing. Platelets, 1-8.
- Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake. Platelets, 1-7.
- Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment. Cardiovascular Drugs and Therapy.
- Choosing a perspective on mortality with DAPT. European Heart Journal, ehv610-ehv610.
- Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. Platelets. View this article in WRRO
- New Antithrombotic Drugs in Acute Coronary Syndrome. Journal of Clinical Medicine, 9(7), 2059-2059.
- Computed tomography chest imaging offers no advantage over chest X-ray in the initial assessment of gestational trophoblastic neoplasia. British Journal of Cancer.
Chapters
Conference proceedings papers
- P28 DOES MILD CORONARY ARTERY ATHEROSCLEROSIS PROGRESS AT SERIAL ANGIOGRAPHY?. Cardiovascular Research, Vol. 114(suppl_2) (pp S9-S9)
- ULTRA-LOW-DOSE TWICE-DAILY ASPIRIN IMPROVES HEMOSTASIS AND MAINTAINS PLATELET INHIBITION IN ACUTE CORONARY SYNDROME PATIENTS RECEIVING TICAGRELOR. Journal of the American College of Cardiology, Vol. 71(11) (pp A30-A30)
- 72 Offset of ticagrelor prior to coronary artery bypass graft surgery (cabg) surgery. Heart, Vol. 103(Suppl 5) (pp A53.2-A54)
- Combining DAPT with a PPI faces the acid test of real-world use. European Heart Journal, 40(24), 1971-1974.
- Teaching interests
-
I contribute to the teaching of medical students at various stages of the MB ChB course, as well as lecturing on the Masters in Cardiovascular Research and Masters in Genomic Medicine programmes.
I am studying for a Postgraduate Certificate in Teaching and Learning for Higher Education with the School of Education at the University of Sheffield.
I am also passionate about public engagement and have recently devised and delivered sessions for the NHS 70th Anniversary celebrations, Sheffield Ignite Academy, Pecha Kucha foundation and the Millennium Galleries, Sheffield (Leonardo Da Vinci exhibition).
- Professional activities
-
I was elected as a Nucleolus member of the European Society of Cardiology Working Group on Thrombosis Young Researchers in October 2018.